MCID: HYP098
MIFTS: 56

Hypereosinophilic Syndrome malady

Categories: Genetic diseases, Rare diseases, Blood diseases, Cancer diseases

Aliases & Classifications for Hypereosinophilic Syndrome

About this section
Sources:
65UMLS, 45NIH Rare Diseases, 22GeneTests, 47Novoseek, 40NCBI Bookshelf, 51Orphanet, 24GTR, 28ICD10 via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Hypereosinophilic Syndrome:

Name: Hypereosinophilic Syndrome 45 22 47 65
Idiopathic Hypereosinophilic Syndrome 47 51 24 65
Hes 45 40
 
Disseminated Eosinophilic Collagen Disease 65
Hypereosinophilic Syndrome, Idiopathic 45

Characteristics:

Orphanet epidemiological data:

51
idiopathic hypereosinophilic syndrome:
Prevalence: 1-5/10000 (Europe); Age of onset: Adult

Classifications:



External Ids:

Orphanet51 3260
ICD10 via Orphanet28 D47.5
UMLS via Orphanet66 C0206141
UMLS65 C0206141, C1540912

Summaries for Hypereosinophilic Syndrome

About this section
NIH Rare Diseases:45 Hypereosinophilic syndrome is a group of rare blood disorders characterized by increased levels of eosinophils (a type of white blood cell that plays a role in the human immune system) persisting for more than six months. the signs and symptoms are due to involvement of several internal organs and there is usually no evidence of parasites, allergy, or other known causes of an elevated eosinophil count. this condition largely occurs in males, typically at middle age. it usually presents with fever, weight loss, fatigue, and rash. an enlarged liver and spleen and liver is often present. the lungs, kidneys, heart, and nervous system can also be affected. last updated: 7/11/2011

MalaCards based summary: Hypereosinophilic Syndrome, also known as idiopathic hypereosinophilic syndrome, is related to budd-chiari syndrome and skin conditions, and has symptoms including myalgia, myalgia and pruritus. An important gene associated with Hypereosinophilic Syndrome is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways are Cytoskeleton remodeling_Role of PDGFs in cell migration and Osteoblast Signaling. The drugs hydroxyurea and interferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include myeloid, liver and heart.

Wikipedia:68 The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil... more...

Related Diseases for Hypereosinophilic Syndrome

About this section

Diseases in the Hypereosinophilic Syndrome family:

Secondary Hypereosinophilic Syndrome Primary Hypereosinophilic Syndrome

Diseases related to Hypereosinophilic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 200)
idRelated DiseaseScoreTop Affiliating Genes
1budd-chiari syndrome29.8FIP1L1, PDGFRA
2skin conditions29.7IL5, RNASE3
3primary hypereosinophilic syndrome12.2
4lymphocytic hypereosinophilic syndrome12.1
5secondary hypereosinophilic syndrome12.1
6hypereosinophilic syndrome, idiopathic, resistant to imatinib11.9
7chronic eosinophilic leukemia10.8
8endomyocardial fibrosis10.7
9aggressive systemic mastocytosis10.4FIP1L1, PDGFRA
10leukemia10.4
11mast cell neoplasm10.4FIP1L1, PDGFRA
12superior mesenteric artery syndrome10.3FIP1L1, PDGFRA
13lymphoma10.2
14kyphoscoliotic heart disease10.2IL5, RNASE3
15papillary conjunctivitis10.2IL5, RNASE3
16bacterial gastritis10.2IL5, RNASE3
17status asthmaticus10.2IL5, RNASE3
18eosinophilia10.2
19keratoconjunctivitis10.2IL5, RNASE3
20loeffler syndrome10.2IL5, RNASE3
21non specific chronic endometritis10.2IL5, RNASE3
22superficial urinary bladder cancer10.2IL5, RNASE3
23endocarditis10.2
24motor peripheral neuropathy10.2IL5, RNASE3
25cerebritis10.2
26melorheostosis10.2IL5, RNASE3
27hepatoid adenocarcinoma10.2IL5, RNASE3
28retroperitoneal germ cell neoplasm10.2IL5, RNASE3
29enamel caries10.2IL5, RNASE3
30winchester syndrome10.1EPX, RNASE3
31balkan nephropathy10.1IL5, RNASE3
32acalculous cholecystitis10.1IL5, RNASE3
33mixed extragonadal germ cell cancer10.1EPX, RNASE3
34opioid abuse10.1IL5, RNASE3
35colitis10.1
36nasopharyngitis10.1IL5, RNASE3
37anus disease10.1EPX, RNASE3
38postcholecystectomy syndrome10.1IL5, RNASE3
39cardiomyopathy10.1
40hodgkin's lymphoma, nodular sclerosis10.1IL5, RNASE3
41orbital plasma cell granuloma10.0IL5, RNASE3
42myocardial infarction10.0
43hepatitis10.0
44peripheral t-cell lymphoma10.0
45gastroenteritis10.0
46restrictive cardiomyopathy10.0
47eosinophilic gastroenteritis10.0
48vasculitis10.0
49hypothyroidism due to deficient transcription factors involved in pituitary development or function10.0PDGFRA, PDGFRB
50diffuse scleroderma10.0IL5, RNASE3

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome:



Diseases related to hypereosinophilic syndrome

Symptoms for Hypereosinophilic Syndrome

About this section

UMLS symptoms related to Hypereosinophilic Syndrome:


myalgia, pruritus, hepatomegaly

Drugs & Therapeutics for Hypereosinophilic Syndrome

About this section

Drugs for Hypereosinophilic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 160)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
MethylprednisoloneapprovedPhase 4108283-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
A-methapred
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Depo-medrol
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Solu-medrol
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
2
PrednisoloneapprovedPhase 4108250-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
Flo-pred
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
MLS001304083
 
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
Millipred
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Omnipred
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
3
Omalizumabapproved, investigationalPhase 4137242138-07-4
Synonyms:
242138-07-4
D05251
Ig gamma-1 chain C region
Omalizumab
 
Omalizumab (USAN/INN)
Omalizumab (genetical recombination)
Omalizumab (genetical recombination) (JAN)
Xolair
Xolair (TN)
4Adrenergic beta-AgonistsPhase 4, Phase 21266
5Protective AgentsPhase 4, Phase 25651
6Adrenergic beta-2 Receptor AgonistsPhase 4, Phase 2741
7Adrenergic AgonistsPhase 4, Phase 22331
8Anti-Allergic AgentsPhase 4, Phase 21312
9Adrenergic AgentsPhase 4, Phase 24204
10Anti-Asthmatic AgentsPhase 4, Phase 22796
11Tocolytic AgentsPhase 4, Phase 2561
12AntiemeticsPhase 4, Phase 23213
13Respiratory System AgentsPhase 4, Phase 23931
14Neurotransmitter AgentsPhase 4, Phase 214795
15Bronchodilator AgentsPhase 4, Phase 22377
16Prednisolone phosphatePhase 41082
17AlbuterolPhase 4, Phase 2384
18Hormone AntagonistsPhase 4, Phase 2, Phase 310002
19HormonesPhase 4, Phase 2, Phase 311748
20glucocorticoidsPhase 4, Phase 2, Phase 33896
21Gastrointestinal AgentsPhase 4, Phase 26401
22Prednisolone hemisuccinatePhase 41082
23Antineoplastic Agents, HormonalPhase 4, Phase 2, Phase 34256
24Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 39988
25Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 38478
26Methylprednisolone acetatePhase 41082
27Prednisolone acetatePhase 41082
28Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 118510
29Neuroprotective AgentsPhase 41376
30Methylprednisolone HemisuccinatePhase 41082
31
EtoposideapprovedPhase 3, Phase 2, Phase 1116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
32
Cytarabineapproved, investigationalPhase 3, Phase 2, Phase 11035147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosyl Cytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine (JP15/USP/INN)
 
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
33
AldesleukinapprovedPhase 338785898-30-2
Synonyms:
IL-2
Interleukin-2 precursor
 
Proleukin
T-cell growth factor
TCGF
34
Busulfanapproved, investigationalPhase 3, Phase 250655-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
35
DaunorubicinapprovedPhase 3, Phase 225220830-81-330323
Synonyms:
(+)-Daunomycin
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
11006-54-5
11048-29-6
1407-15-4
149541-57-1
20830-81-3
23942-76-9
27576-81-4
28020-80-6
AB00514669
AC1L1JCP
AC1Q29OI
AI3-52942
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Antibiotics from Streptomyces coeruleorubidus
BPBio1_000389
BRD-K43389675-003-02-7
BRN 1445583
BSPBio_000353
C01907
CCRIS 914
CHEBI:41977
CHEMBL178
CID30323
Cerubidin
Cerubidine
D07776
DAUNORUBICIN HCL
DB00694
DM1
Daunamycin
Daunarubicinum
Dauno-Rubidomycine
DaunoXome
DaunoXome (TN)
Daunoblastin
Daunoblastine
Daunomycin
 
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
Daunorubicin
Daunorubicin (INN)
Daunorubicin (liposomal)
Daunorubicin Hcl
Daunorubicin Hydrochloride
Daunorubicin [INN:BAN]
Daunorubicin, Hydrochloride
Daunorubicina
Daunorubicine
Daunorubicinum
Daunorubicinum [INN-Latin]
Daunoxome
EINECS 244-069-7
FI 6339
FI6339
HMS2089H04
HMS2091K06
HSDB 5095
LMPK13050002
LS-187381
LS-997
Leukaemomycin C
MolPort-002-533-961
NCGC00024246-05
NCGC00024246-06
NCGC00025173-01
NCI-C04693
NChemBio.2007.10-comp14
NSC 83142
NSC-82151
Ondena
Prestwick3_000487
RCRA waste no. U059
RP 13057
Rcra Waste No. U059
Rp 13057 Hydrochloride
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
Tocris-1467
UNII-ZS7284E0ZP
VS-103
daunorubicin
nchembio723-comp2
36
AsparaginaseapprovedPhase 32019015-68-3
Synonyms:
Elspar
Erwinase
 
Kidrolase
L-asparagine amidohydrolase
Putative L-asparaginase precursor
37
ThioguanineapprovedPhase 377154-42-72723601
Synonyms:
154-42-7
2 Amino 6 Purinethiol
2-Amino 6MP
2-Amino 6mp
2-Amino-1,7-dihydro-6H-purin-6-thion
2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]
2-Amino-1,7-dihydro-6H-purine-6-thione
2-Amino-6-MP
2-Amino-6-mercaptopurine
2-Amino-6-merkaptopurin
2-Amino-6-merkaptopurin [Czech]
2-Amino-6-purinethiol
2-Amino-9H-purine-6-thiol
2-Aminopurin-6-thiol
2-Aminopurin-6-thiol [Czech]
2-Aminopurine-6(1H)-thione
2-Aminopurine-6-thiol
2-Thioguanine
2-amino-1,9-Dihydropurine-6-thione
2-amino-1H-purine-6(7H)-thione
2-amino-3,7-dihydropurine-6-thione
2-aminopurine-6-thiol
5580-03-0
6 Thioguanine
6-Mercapto-2-aminopurine
6-Mercaptoguanine
6-TG
6-Thioguanine
6-Thioguanine (6-TG)
6-Thioguanine, Thioguanine
A4660_SIGMA
A4882_SIGMA
AC-11125
AC1MC379
AI3-26078
AKOS003389499
BSPBio_001994
BW 5071
C07648
C5H7N5S
CCRIS 8997
CHEBI:136864
CHEMBL727
CID2723601
D013866
D08603
DB00352
DX4
DivK1c_000428
EINECS 205-827-2
FT-0083572
Glaxo Wellcome Brand of Thioguanine
Glaxo Wellcome Brand of Tioguanine
GlaxoSmithKline Brand of Thioguanine
GlaxoSmithKline Brand of Tioguanine
Guanine, thio- (VAN)
HMS1921E09
HMS2092M11
HMS501F10
HSDB 2504
I14-1541
IDI1_000428
KBio1_000428
KBio2_000715
KBio2_002476
KBio2_003283
KBio2_005044
 
KBio2_005851
KBio2_007612
KBio3_001494
KBio3_002954
KBioGR_001452
KBioGR_002476
KBioSS_000715
KBioSS_002483
LS-888
LT00455187
Lanvis
Lanvis (TN)
MLS001333131
MLS001333132
MolPort-000-929-106
MolPort-001-813-204
MolPort-003-984-174
NCGC00094792-01
NCGC00094792-02
NCGC00094792-03
NCI60_041643
NCIOpen2_004153
NINDS_000428
NSC 752
NSC-752
NSC752
S1774_Selleck
SBB067147
SMP2_000326
SMR000857244
SPBio_000849
SPECTRUM1500573
ST50298831
Spectrum2_000695
Spectrum3_000577
Spectrum4_000926
Spectrum5_001455
Spectrum_000235
T0212
TG
THG
Tabloid
ThG
Thioguanin GSK
Thioguanin-GSK
ThioguaninGSK
Thioguanine
Thioguanine Hemihydrate
Thioguanine Monosodium Salt
Thioguanine Tabloid
Thioguanine [USAN:BAN]
Tioguanin
Tioguanina
Tioguanina Wellcome
Tioguanina [INN-Spanish]
Tioguanine
Tioguanine (INN)
Tioguanine GlaxoSmithKline Brand
Tioguaninum
Tioguaninum [INN-Latin]
UNII-FTK8U1GZNX
UNII-WIX31ZPX66
WLN: T56 BNM FYM INJ FUS HZ
Wellcome Brand of Thioguanine
Wellcome U3B
ZINC18085533
cMAP_000061
purine antimetabolite: antimetabolite: inhibits nucleic acid replication
thioguanine
38
PrednisoneapprovedPhase 2, Phase 3126753-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
Juvason
 
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Perrigo Prednisone
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rayos
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
39Interleukin-2Phase 3487
40lenograstimPhase 3, Phase 21134
41Pharmaceutical SolutionsPhase 3, Phase 27004
42Immunosuppressive AgentsPhase 3, Phase 2, Phase 110422
43ImmunoglobulinsPhase 3, Phase 24477
44Antibodies, MonoclonalPhase 3, Phase 22413
45AntibodiesPhase 3, Phase 24477
46Topoisomerase InhibitorsPhase 3, Phase 1, Phase 24081
47Antibiotics, AntitubercularPhase 3, Phase 1, Phase 25971
48Anti-Infective AgentsPhase 3, Phase 2, Phase 117220
49AnalgesicsPhase 3, Phase 2, Phase 19358
50Anti-Bacterial AgentsPhase 3, Phase 1, Phase 29140

Interventional clinical trials:

(show top 50)    (show all 83)
idNameStatusNCT IDPhase
1The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic PneumoniaCompletedNCT00632554Phase 4
2Steroid Treatment for Hypereosinophilic SyndromeRecruitingNCT01524536Phase 4
3Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma PatientsRecruitingNCT02654145Phase 4
4Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic SyndromeCompletedNCT00097370Phase 3
5Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
6Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006363Phase 3
7Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe AsthmaCompletedNCT01508936Phase 3
8A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01287039Phase 3
9A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic AsthmaCompletedNCT01285323Phase 3
10A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic AsthmaCompletedNCT01270464Phase 3
11Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)RecruitingNCT00244686Phase 3
12Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY StudyRecruitingNCT02594332Phase 3
13Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma PatientsRecruitingNCT02555371Phase 3
14Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic SyndromesActive, not recruitingNCT00369317Phase 3
15Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantActive, not recruitingNCT01305200Phase 3
16Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma ControlActive, not recruitingNCT02281318Phase 3
17Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic AsthmaEnrolling by invitationNCT02559791Phase 2, Phase 3
18Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic AsthmaTerminatedNCT01290887Phase 3
19Anti-Interleukin-5 Antibody to Treat Hypereosinophilic SyndromeCompletedNCT00017862Phase 2
20Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)CompletedNCT00086658Phase 2
21Efficacy of Imatinib Mesylate in Hypereosinophilic SyndromesCompletedNCT00787384Phase 2
22Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic SyndromeCompletedNCT00266565Phase 1, Phase 2
23A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related CancersCompletedNCT00109707Phase 1, Phase 2
242-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)CompletedNCT00483067Phase 2
25Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
26Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
27Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1, Phase 2
28Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
29Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2
30Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00027872Phase 2
31Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid LeukemiaCompletedNCT00666588Phase 2
32Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00407966Phase 2
333-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2
34Lenalidomide in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00352365Phase 2
35A Phase IIa Study of KHK4563CompletedNCT01412736Phase 2
36Efficacy, Safety, and Tolerability of SAR231893 (REGN668) in Patients With Persistent Moderate to Severe Eosinophilic AsthmaCompletedNCT01312961Phase 2
37Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic SyndromeRecruitingNCT00044304Phase 2
38Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic LeukemiasRecruitingNCT00276926Phase 2
39Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic SyndromeRecruitingNCT02101138Phase 2
40Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic SyndromeRecruitingNCT02130882Phase 2
41A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesRecruitingNCT01384513Phase 2
42Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyRecruitingNCT02071901Phase 2
43Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in ChildrenRecruitingNCT02377427Phase 2
44Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)Active, not recruitingNCT00255346Phase 2
45Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisActive, not recruitingNCT00555581Phase 2
46Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01627041Phase 2
47Effect of OC000459 on Eosinophilic Airway Inflammation in Severe AsthmaNot yet recruitingNCT02560610Phase 2
48A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic SyndromeTerminatedNCT00171860Phase 2
49Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00096148Phase 2
50Cilengitide in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT00089388Phase 2

Search NIH Clinical Center for Hypereosinophilic Syndrome

Inferred drug relations via UMLS65/NDF-RT43:

Genetic Tests for Hypereosinophilic Syndrome

About this section

Genetic tests related to Hypereosinophilic Syndrome:

id Genetic test Affiliating Genes
1 Hypereosinophilic Syndrome22 PDGFRA

Anatomical Context for Hypereosinophilic Syndrome

About this section

MalaCards organs/tissues related to Hypereosinophilic Syndrome:

33
Myeloid, Liver, Heart, Bone, Bone marrow, Lung, Kidney

Animal Models for Hypereosinophilic Syndrome or affiliated genes

About this section

Publications for Hypereosinophilic Syndrome

About this section

Articles related to Hypereosinophilic Syndrome:

(show top 50)    (show all 615)
idTitleAuthorsYear
1
Atypical Presentation of Intracardiac Floating Thrombi in Hypereosinophilic Syndrome Complicated With Stroke and Systemic Embolization: A Case Report. (26512591)
2015
2
MRI-based Evidence for Myocardial Involvement in Women with Hypereosinophilic Syndrome. (25740233)
2015
3
A Rare Case of Aortic Valve Thrombosis in Patient with Idiopathic Hypereosinophilic Syndrome. (26435854)
2015
4
CD30+ clonal T-cell lymphoid proliferation of the skin in a patient with hypereosinophilic syndrome. (25421540)
2015
5
Endobronchial Involvement in Idiopathic Hypereosinophilic Syndrome. (26492606)
2015
6
Hypereosinophilic syndrome with large intracardiac thrombus. (25189313)
2014
7
Pediatric idiopathic hypereosinophilic syndrome with Gianotti-Crosti syndrome: a novel presentation. (24738625)
2014
8
Eosinophilic cystitis presented as a manifestation of hypereosinophilic syndrome: a case report and review of the literature. (23573073)
2013
9
Hypereosinophilic syndrome masquerading as a myocardial infarction causing decompensated heart failure. (24053402)
2013
10
Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome. (23669338)
2013
11
A case of dermatopathic lymphadenopathy associated with hypereosinophilic syndrome. (22499479)
2012
12
Gadolinium-enhanced cardiovascular magnetic resonance for the detection and characterization of Loeffler endocarditis in patients with hypereosinophilic syndrome. (21963210)
2011
13
Hypereosinophilic syndrome presenting with large left ventricular apical thrombus and pulmonary embolism. (21854430)
2011
14
An 8-year-old boy with hypereosinophilic syndrome. (21646806)
2011
15
Medical therapy alone produces regression of combined aortic and mitral valve involvement in hypereosinophilic syndrome. (20956234)
2010
16
Hypereosinophilic syndromes: pathogenic and therapeutic up-to-date]. (20303627)
2010
17
The proportion of CD3- CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES). (20883323)
2010
18
Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. (20810155)
2010
19
Wells Syndrome with Multiorgan Involvement Mimicking Hypereosinophilic Syndrome. (20652113)
2009
20
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. (19210352)
2009
21
Successful treatment of refractory idiopathic hypereosinophilic syndrome with etoposide. (19142161)
2009
22
Oral mucosa lesions in hypereosinophilic syndrome--an update. (18194138)
2008
23
Hypereosinophilic syndrome with isolated Loeffler's endocarditis: complete resolution with corticosteroids. (18480530)
2008
24
Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid. (17261495)
2007
25
Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. (17097375)
2007
26
Factor V Leiden mutation and deep venous thrombosis in a patient with hypereosinophilic syndrome. (16951787)
2006
27
Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia. (23662039)
2006
28
Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. (16612767)
2006
29
Control of hypereosinophilic syndrome-associated recalcitrant coronary artery spasm by combined treatment with prednisone, imatinib mesylate and hydroxyurea. (18651015)
2006
30
Selective priming of peripheral blood eosinophils in patients with idiopathic hypereosinophilic syndrome. (17078855)
2006
31
Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. (15995323)
2005
32
Thrombotic microangiopathy associated with the hypereosinophilic syndrome. (15840027)
2005
33
The hypereosinophilic syndrome: idiopathic or not, that is the question. (15921372)
2005
34
Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant. (15609294)
2005
35
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. (14984510)
2004
36
Successful treatment of hypereosinophilic syndrome after remission of acute lymphoblastic leukemia in a patient who underwent non-myeloablative stem cell transplantation. (15075099)
2004
37
Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. (15621768)
2004
38
Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. (15070668)
2004
39
Imatinib-mesylate for all patients with hypereosinophilic syndrome? (15158099)
2004
40
Idiopathic hypereosinophilic syndrome manifesting as pulmonary oedema. (12723663)
2003
41
Hypereosinophilic dermatosis: skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome? (10971369)
2000
42
Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. (9829847)
1998
43
Wells' syndrome associated with idiopathic hypereosinophilic syndrome. (9470919)
1997
44
Sclerosing cholangitis associated with hypereosinophilic syndrome. (9260773)
1997
45
Hypereosinophilic syndrome or chronic eosinophilic leukemia: report of a case with a lytic bone lesion. (9180305)
1997
46
Idiopathic hypereosinophilic syndrome and pregnancy. (9197455)
1997
47
alpha-Interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission. (7718904)
1995
48
49
50

Variations for Hypereosinophilic Syndrome

About this section

Expression for genes affiliated with Hypereosinophilic Syndrome

About this section
Search GEO for disease gene expression data for Hypereosinophilic Syndrome.

Pathways for genes affiliated with Hypereosinophilic Syndrome

About this section

Pathways related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 31)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.4PDGFRA, PDGFRB
29.4PDGFRA, PDGFRB
39.4PDGFRA, PDGFRB
49.4IL5, RNASE3
5
Show member pathways
9.3PDGFRB, RNASE3
69.3PDGFRB, RNASE3
79.1EPX, RNASE3
8
Show member pathways
8.9IL5, PDGFRA, PDGFRB
9
Show member pathways
8.9PDGFRA, PDGFRB, RNASE3
10
Show member pathways
8.9PDGFRA, PDGFRB, RNASE3
118.9PDGFRA, PDGFRB, RNASE3
12
Show member pathways
8.9PDGFRA, PDGFRB, RNASE3
138.9PDGFRA, PDGFRB, RNASE3
14
Show member pathways
8.9PDGFRA, PDGFRB, RNASE3
158.9PDGFRA, PDGFRB, RNASE3
168.9PDGFRA, PDGFRB, RNASE3
17
Show member pathways
8.9PDGFRA, PDGFRB, RNASE3
18
Show member pathways
8.9PDGFRA, PDGFRB, RNASE3
19
Show member pathways
8.9PDGFRA, PDGFRB, RNASE3
20
Show member pathways
8.9PDGFRA, PDGFRB, RNASE3
21
Show member pathways
8.9PDGFRA, PDGFRB, RNASE3
22
Show member pathways
8.9PDGFRA, PDGFRB, RNASE3
238.9PDGFRA, PDGFRB, RNASE3
248.9PDGFRA, PDGFRB, RNASE3
25
Show member pathways
8.6EPX, IL5, RNASE3
26
Show member pathways
8.4IL5, PDGFRA, PDGFRB, RNASE3
27
Show member pathways
8.4IL5, PDGFRA, PDGFRB, RNASE3
288.1EPX, PDGFRA, PDGFRB, RNASE3
29
Show member pathways
8.1EPX, PDGFRA, PDGFRB, RNASE3
30
Show member pathways
7.6EPX, IL5, PDGFRA, PDGFRB, RNASE3
31
Show member pathways
7.6EPX, IL5, PDGFRA, PDGFRB, RNASE3

GO Terms for genes affiliated with Hypereosinophilic Syndrome

About this section

Biological processes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of phospholipase C activityGO:00108639.9PDGFRA, PDGFRB
2retina vasculature development in camera-type eyeGO:00612989.9PDGFRA, PDGFRB
3regulation of phosphatidylinositol 3-kinase signalingGO:00140669.9PDGFRA, PDGFRB
4phosphatidylinositol-mediated signalingGO:00480159.9PDGFRA, PDGFRB
5platelet-derived growth factor receptor signaling pathwayGO:00480089.9PDGFRA, PDGFRB
6wound healingGO:00420609.8PDGFRA, PDGFRB
7transmembrane receptor protein tyrosine kinase signaling pathwayGO:00071699.8PDGFRA, PDGFRB
8positive regulation of phosphatidylinositol 3-kinase signalingGO:00140689.7PDGFRA, PDGFRB
9peptidyl-tyrosine phosphorylationGO:00181089.7IL5, PDGFRB
10positive regulation of phosphatidylinositol 3-kinase activityGO:00435529.6PDGFRA, PDGFRB
11cell chemotaxisGO:00603269.3PDGFRA, PDGFRB
12fibroblast growth factor receptor signaling pathwayGO:00085439.1IL5, PDGFRA, PDGFRB
13insulin receptor signaling pathwayGO:00082868.9IL5, PDGFRA, PDGFRB
14activation of MAPKK activityGO:00001868.6IL5, PDGFRA, PDGFRB

Molecular functions related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1platelet-derived growth factor bindingGO:00484079.6PDGFRA, PDGFRB
2vascular endothelial growth factor bindingGO:00380859.5PDGFRA, PDGFRB
3protein tyrosine kinase activityGO:00047138.9IL5, PDGFRA, PDGFRB

Sources for Hypereosinophilic Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet